141 related articles for article (PubMed ID: 19156258)
1. Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease.
Bica L; Crouch PJ; Cappai R; White AR
Mol Biosyst; 2009 Feb; 5(2):134-42. PubMed ID: 19156258
[TBL] [Abstract][Full Text] [Related]
2. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
3. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS; Rauw G; Baker GB; Kar S
Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
[TBL] [Abstract][Full Text] [Related]
4. Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide.
Price KA; Filiz G; Caragounis A; Du T; Laughton KM; Masters CL; Sharples RA; Hill AF; Li QX; Donnelly PS; Barnham KJ; Crouch PJ; White AR
Int J Biochem Cell Biol; 2008; 40(9):1901-17. PubMed ID: 18346929
[TBL] [Abstract][Full Text] [Related]
5. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
Crouch PJ; White AR; Bush AI
FEBS J; 2007 Aug; 274(15):3775-83. PubMed ID: 17617225
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
7. Role of melatonin in Alzheimer-like neurodegeneration.
Wang JZ; Wang ZF
Acta Pharmacol Sin; 2006 Jan; 27(1):41-9. PubMed ID: 16364209
[TBL] [Abstract][Full Text] [Related]
8. Sustained activation of glial cell epidermal growth factor receptor by bis(thiosemicarbazonato) metal complexes is associated with inhibition of protein tyrosine phosphatase activity.
Price KA; Caragounis A; Paterson BM; Filiz G; Volitakis I; Masters CL; Barnham KJ; Donnelly PS; Crouch PJ; White AR
J Med Chem; 2009 Nov; 52(21):6606-20. PubMed ID: 19807095
[TBL] [Abstract][Full Text] [Related]
9. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation.
Sul D; Kim HS; Lee D; Joo SS; Hwang KW; Park SY
Life Sci; 2009 Feb; 84(9-10):257-62. PubMed ID: 19101570
[TBL] [Abstract][Full Text] [Related]
13. Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades.
Xu Y; Hou XY; Liu Y; Zong YY
J Neurosci Res; 2009 Mar; 87(4):918-27. PubMed ID: 18951497
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Crouch PJ; Savva MS; Hung LW; Donnelly PS; Mot AI; Parker SJ; Greenough MA; Volitakis I; Adlard PA; Cherny RA; Masters CL; Bush AI; Barnham KJ; White AR
J Neurochem; 2011 Oct; 119(1):220-30. PubMed ID: 21797865
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?
Muyllaert D; Kremer A; Jaworski T; Borghgraef P; Devijver H; Croes S; Dewachter I; Van Leuven F
Genes Brain Behav; 2008 Feb; 7 Suppl 1():57-66. PubMed ID: 18184370
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
Crouch PJ; Barnham KJ; Bush AI; White AR
Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands.
Caragounis A; Du T; Filiz G; Laughton KM; Volitakis I; Sharples RA; Cherny RA; Masters CL; Drew SC; Hill AF; Li QX; Crouch PJ; Barnham KJ; White AR
Biochem J; 2007 Nov; 407(3):435-50. PubMed ID: 17680773
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid.
Sun ZK; Yang HQ; Pan J; Zhen H; Wang ZQ; Chen SD; Ding JQ
J Neurosci Res; 2008 Oct; 86(13):3018-27. PubMed ID: 18512763
[TBL] [Abstract][Full Text] [Related]
19. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.
Fan J; Donkin J; Wellington C
Biofactors; 2009; 35(3):239-48. PubMed ID: 19472365
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress signalling in Alzheimer's disease.
Zhu X; Raina AK; Lee HG; Casadesus G; Smith MA; Perry G
Brain Res; 2004 Mar; 1000(1-2):32-9. PubMed ID: 15053949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
